English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Mutations in the isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2)appear to occur frequently and selectively in gliomas. Our aim was to assess whetherIDH mutations are common in Chinese glioma patients and whether the mutationspredict good response to concomitant chemoradiotherapy. In this study IDH1 andIDH2 mutations were detected in a series of 203 gliomas. IDH1 mutations were presentin 75 of the 203 cases (36.9%) while IDH2 mutations in 5 of the 203 cases (2.5%).No tumor was mutated in both IDH1 and IDH2. IDH1/2 mutations were associated withprolonged overall survival in the whole series of patients exclusive of pilocyticastrocytoma (P&lt;0.001), WHO grade Ⅱ patients who received no adjuvant therapyafter surgery (P=0.014) and WHO grade Ⅲ patients who received concomitant chemoradiotherapy(standard schedule) after surgery (P=0.033). Furthermore, there was no correlationbetween IDH1/2 mutations and reponse to concomitant chemoradiotherapy in anaplasticgliomas. Our results suggest that IDH1 mutations also occur freuqently in Chineseglioma patients but the frequency of IDH1 mutations is below the findings reportedby North American and European groups. Furthermore, we confirm the prognosticsignificance of IDH1/2 mutations in gliomas, but the mutations cannot predicta favorable response to concomitant chemoradiotherapy in anaplastic gliomas.

oncology reports

IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas